ICON Appoints Alan Morgan To Role Of Group President, Clinical Research Services
20 Août 2010 - 10:00AM
Business Wire
ICON plc (NASDAQ:ICLR) (ISIN:IE0005711209), a global
provider of outsourced development services to the pharmaceutical,
biotechnology and medical device industries, today announced the
appointment of Mr. Alan Morgan to the position of Group President,
Clinical Research Services.
Mr. Morgan is currently Group President, ICON Early Phase and
Laboratory Services, and prior to that was Chief Operating Officer
of the ICON Clinical Research division, having joined ICON in 2006.
Alan has over 20 years experience working in both the
pharmaceutical and the CRO industries. Prior to joining ICON, he
was Vice President and Global General Manager of the Phase II/IV
business of MDS Pharma Services, and he has also held senior
positions in Covance, Glaxo Wellcome and ICI Pharmaceuticals.
ICON also announced that Ms Linda Meyerson has joined the
company as Chief Operating Officer, ICON Clinical Research. Ms
Meyerson will report directly to Mr. Morgan and brings over 30
years of pharmaceutical industry experience and drug development
knowledge to the organisation. Prior to joining ICON, Ms Meyerson
was Vice President, Global Clinical Operations for GlaxoSmithKline,
having previously served in a similar global capacity for the
Janssen Research Foundation and the RW Johnson Pharmaceutical
Research Institute.
ICON also announced that Dr. John Hubbard, the former Group
President, Clinical Research Services, is leaving the organisation
to take up a senior role in a leading global biopharmaceutical
company.
Commenting on the organisational changes, Mr. Peter Gray, CEO
ICON plc said, "I would like to welcome Alan to his new role. He
has been an outstanding member of our management team, and his deep
knowledge of our clinical organisation and broad industry
experience will be invaluable as we continue to develop our
business." Mr Gray added, “We are also delighted to welcome Linda
to our team. Her extensive global drug development experience will
be a huge asset to the organisation. We are sorry to lose John
Hubbard, and I would like to acknowledge his outstanding
contribution to ICON and wish him every success in his new
challenging role.”
About ICON plc
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries.
The Company specialises in the strategic development, management
and analysis of programs that support clinical development - from
compound selection to Phase I-IV clinical studies. With
headquarters in Dublin, Ireland, ICON currently operates from 71
locations in 39 countries and has approximately 7,500 employees.
Further information is available at www.iconplc.com.
ICON/ICLR-G
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024